This site is intended for healthcare professionals
Drug information


Read time: 14 mins
Last updated: 06 May 2020
Published: 01 Apr 2021

4.1 Therapeutic indications

a) the control of hypertension;

b) the management of angina pectoris;

c) long term management against re-infarction after recovery from acute myocardial infarction;

d) the control of most forms of cardiac dysrhythmias;

e) the prophylaxis of migraine;

f) the management of essential tremor;

g) relief of situational anxiety and generalised anxiety symptoms, particularly those of somatic type;

h) prophylaxis of upper gastrointestinal bleeding in patients with portal hypertension and oesophageal varices;

i) the adjunctive management of thyrotoxicosis and thyrotoxic crisis;

j) management of hypertrophic obstructive cardiomyopathy;

k) management of phaeochromocytoma peri-operatively (with an alpha- blocker).

Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.




The drug SPC information (indications, contra-indications, interactions, etc), has been developed in collaboration with eMC ( Medthority offers the whole library of SPC documents from eMC.

Medthority will not be held liable for explicit or implicit errors, or missing data.

Reporting of suspected adverse reactions 

Drug Licencing

Drugs appearing in this section are approved by UK Medicines & Healthcare Products Regulatory Agency (MHRA), & the European Medicines Agency (EMA).